<DOC>
	<DOCNO>NCT00504348</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety combination treatment tacrolimus corticosteroid polymyositis/dermatomyositis patient interstitial pneumonitis comparison corticosteroid-treated historical control .</brief_summary>
	<brief_title>Investigation Myositis-associated Pneumonitis Prednisolone And Concomitant Tacrolimus</brief_title>
	<detailed_description />
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Polymyositis</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Experimental treatment group 1 . Diagnosis definite probable polymyositis dermatomyositis criterion Bohan et al , clinicallyamyopathic dermatomyositis definition propose Sontheimer et al 2 . Highresolution CT finding consistent interstitial pneumonitis , confirm radiologist . If consolidation abnormal finding , patient must pathologically document evidence interstitial pneumonitis histological type cryptogenic organize pneumonia/bronchiolitis obliterans organize pneumonia ( patient could one histological type include cryptogenic organize pneumonia/bronchiolitis obliterans organize pneumonia ) 3 . Meet two follow criterion ( must include 1 ) 1 . Serum KL6 upper normal limit 2 . Presence dyspnea exertion ( grade 2 Magnitude Task component Mahler Modified Dyspnea Index 3 . PaO2 le 80 mmHg breathe ambient air rest , accompany abnormal increase PaCO2 4 . Vital capacity &lt; 80 % predict , diffuse capacity carbon monoxide &lt; 65 % predict 5 . Meet least one follow condition 12week period ( 84 day ) prior initiation study drug Decrease either % forced vital capacity % diffuse capacity carbon monoxide 10 % Worsening interstitial pneumonitis finding chest CT , confirm radiologist 4 . 16 74 year age Historical control group 1 . Diagnosis definite probable polymyositis dermatomyositis criterion Bohan et al , clinicallyamyopathic dermatomyositis definition propose Sontheimer et al 2 . Highresolution CT finding consistent interstitial pneumonitis , confirm radiologist . If consolidation abnormal finding , patient must pathologically document evidence interstitial pneumonitis histological type cryptogenic organize pneumonia/bronchiolitis obliterans organize pneumonia ( patient could one histological type include cryptogenic organize pneumonia/bronchiolitis obliterans organize pneumonia ) 3 . Meet two follow criterion ( must include 1 ) 1 . Serum KL6 upper normal limit 2 . Presence dyspnea exertion ( grade 2 Magnitude Task component Mahler Modified Dyspnea Index 3 . PaO2 le 80 mmHg breathe ambient air rest , accompany abnormal increase PaCO2 4 . Vital capacity &lt; 80 % predict , diffuse capacity carbon monoxide &lt; 65 % predict 5 . Meet least one follow condition 12week period ( 84 day ) prior initiation study drug Decrease either % forced vital capacity % diffuse capacity carbon monoxide 10 % Worsening interstitial pneumonitis finding chest CT , confirm radiologist 4 . Use corticosteroids dos equivalent 0.6 1.0mg/kg/day prednisolone 14 day longer treat interstitial pneumonitis day inclusion criterion ( 3 ) meet ( two course pulse IV corticosteroid therapy within first 28 day allow ) 5 . 16 74 year age Experimental treatment group 1 . Use corticosteroids dos equivalent high prednisolone 0.6mg/kg/day within 4 week ( 28 day ) prior initiation study drug 2 . Use immunosuppressive agent corticosteroid within 12 week ( 84 day ) prior initiation study drug 3 . Could exclude follow condition clinical ground : druginduced pneumonitis , occupational lung disease , hypersensitivity pneumonitis , radiationinduced lung injury 4 . Presence endstage interstitial pneumonitis identify basis vital capacity &lt; 45 % predict , diffuse capacity carbon monoxide &lt; 30 % predict , lung CT predominantly honeycomb appearance 5 . Presence pancreatitis 6 . Presence diabetes mellitus exception glucocorticoidinduced one wellcontrolled ( HbA1c &lt; 6.5 % ) 7 . Serum creatinine 1.5 mg/dL 8 . Presence liver dysfunction ( AST ( GOT ) ALT ( GPT ) great 2.5 time upper limit normal ) exception one consider due myositis accompany elevation muscle enzyme upper limit normal 9 . Serum potassium upper limit normal 10 . Presence ischemic heart disease , arrhythmia require treatment , congestive heart failure , pulmonary hypertension require treatment 11 . Presence history malignancy exception without relapse treatment 5 year longer 12 . Presence serious active infection 13 . Presence active hepatitis B , hepatitis C , HIV infection 14 . History severe drug hypersensitivity reaction 15 . Patients pregnant breastfeeding , patient intend whose spouse intend conceive course study , include followup period 16 . Participation another clinical trial postmarketing clinical study within 26 week ( 182 day ) prior screen 17 . Other medical condition , investigator ` judgment , may associate increase risk subject may interfere study assessment outcomes Historical control group 1 . Use immunosuppressive agent corticosteroid within 12 week ( 84 day ) prior 2 week ( 14 day ) corticosteroid treatment define inclusion criterion ( 4 ) initiate 2 . Could exclude follow condition clinical ground : druginduced pneumonitis , occupational lung disease , hypersensitivity pneumonitis , radiationinduced lung injury 3 . Presence endstage interstitial pneumonitis identify basis vital capacity &lt; 45 % predict , diffuse capacity carbon monoxide &lt; 30 % predict , lung CT predominantly honeycomb appearance 4 . Presence pancreatitis 5 . Presence diabetes mellitus exception glucocorticoidinduced one wellcontrolled ( HbA1c &lt; 6.5 % ) 6 . Serum creatinine 1.5 mg/dL 7 . Presence liver dysfunction ( AST ( GOT ) ALT ( GPT ) great 2.5 time upper limit normal ) exception one consider due myositis accompany elevation muscle enzyme upper limit normal 8 . Serum potassium upper limit normal 9 . Presence ischemic heart disease , arrhythmia require treatment , congestive heart failure , pulmonary hypertension require treatment 10 . Presence history malignancy exception without relapse treatment 5 year longer 11 . Presence serious active infection include active hepatitis B , hepatitis C , HIV infection 12 . Other medical condition , investigator ` judgment , may associate increase risk subject may interfere study assessment outcome</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Interstitial pneumonitis</keyword>
	<keyword>Polymyositis</keyword>
	<keyword>Dermatomyositis</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Corticosteroids</keyword>
	<keyword>Interstitial pneumonitis associate polymyositis dermatomyositis</keyword>
</DOC>